Cargando…

Randomized controlled trial of single‐agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study

Aims/Introduction: To compare first‐line, single‐agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes uncontrolled by diet and exercise with respect to glycemic control, safety and metabolic changes. Materials and Methods: Patients with previously untreated type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shihara, Nobuyuki, Kitaoka, Masafumi, Inagaki, Nobuya, Kadowaki, Takashi, Koumoto, Seisuke, Satoh, Jo, Terauchi, Yasuo, Nunoi, Kiyohide, Yamada, Yuichiro, Sakamaki, Hiroyuki, Seino, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2011
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019308/ https://www.ncbi.nlm.nih.gov/pubmed/24843519 http://dx.doi.org/10.1111/j.2040-1124.2011.00115.x

Ejemplares similares

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2007)

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
por: Yabe, Daisuke, et al.
Publicado: (2022)

Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study
por: Tamura, Haruka, et al.
Publicado: (2022)

Deduction of the operable design space of RP-HPLC technique for the simultaneous estimation of metformin, pioglitazone, and glimepiride
por: Marie, Aya A., et al.
Publicado: (2023)

Effects of Repaglinide Versus Glimepiride on 1,5-Anhydroglucutol and Glycated Hemoglobin Levels in Japanese Patients With Type 2 Diabetes
por: Yamada, Hodaka, et al.
Publicado: (2018)

Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats
por: Rao, Ravi Prakash, et al.
Publicado: (2011)

Aspirin potentiates blood glucose lowering effect of glimepiride-pioglitazone combination in streptozotocin-induced diabetic rats
por: Bag, Soumita, et al.
Publicado: (2014)

Development and validation of the liquid chromatographic method for simultaneous estimation of metformin, pioglitazone, and glimepiride in pharmaceutical dosage forms
por: Pandit, Vinay, et al.
Publicado: (2012)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Relationship between urinary sodium excretion and pioglitazone‐induced edema
por: Nakamura, Akinobu, et al.
Publicado: (2010)

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study
por: Seino, Yutaka, et al.
Publicado: (2017)

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: a randomized prospective study
por: Ragazzi, Eugenio, et al.
Publicado: (2023)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Sensory and motor physiological functions are impaired in gastric inhibitory polypeptide receptor‐deficient mice
por: Okawa, Tetsuji, et al.
Publicado: (2014)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways
por: Kubota, Tetsuya, et al.
Publicado: (2016)

Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
por: Kim, Jeong Mi, et al.
Publicado: (2020)

Analysis of factors influencing postprandial C‐peptide levels in Japanese patients with type 2 diabetes: Comparison with C‐peptide levels after glucagon load
por: Funakoshi, Shogo, et al.
Publicado: (2011)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial
por: Kondo, Yaeko, et al.
Publicado: (2016)

Actual condition survey regarding mismatch of measurements between radioimmunoassay and enzyme‐linked immunosorbent assay tests for anti‐glutamic acid decarboxylase antibody in real‐world clinical practice
por: Oikawa, Yoichi, et al.
Publicado: (2018)

Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese
por: Mitsui, Rie, et al.
Publicado: (2012)

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial
por: Espeland, Mark A., et al.
Publicado: (2020)

Utility of indices using C‐peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes
por: Funakoshi, Shogo, et al.
Publicado: (2011)

Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes
por: Ishii, Hiroaki, et al.
Publicado: (2014)

Solid‐phase extraction treatment is required for measurement of active glucagon‐like peptide‐1 by enzyme‐linked immunosorbent assay kit affected by heterophilic antibodies
por: Hasegawa, Tomonori, et al.
Publicado: (2018)

Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study
por: Yamada, Yuichiro, et al.
Publicado: (2018)

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes
por: Kashiwagi, Atsunori, et al.
Publicado: (2011)

Formulation and characterization of orodispersible tablet of glimepiride
por: Kinani, Ahmad AB Yosef, et al.
Publicado: (2022)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
por: Kim, Hae Jin, et al.
Publicado: (2022)

G protein‐coupled receptor 119 agonist DS‐8500a effects on pancreatic β‐cells in Japanese type 2 diabetes mellitus patients
por: Watada, Hirotaka, et al.
Publicado: (2018)

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial (STOP‐OB)
por: Kitazawa, Toru, et al.
Publicado: (2020)

Efficacy and safety of the G protein‐coupled receptor 119 agonist DS‐8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo‐controlled study
por: Terauchi, Yasuo, et al.
Publicado: (2018)

Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
por: Yabe, Daisuke, et al.
Publicado: (2010)

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials
por: Araki, Eiichi, et al.
Publicado: (2021)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c6s1k0rjjkj6raku6v50hg2596